Sign In | Join Free | My
Shanghai Poochun Industry Co.,Ltd
Better Health Better Life
Home > Medicine Raw Material >

98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceuti

98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceuti

Brand Name : PooChun
Model Number : CAS 98319-26-7
Certification : ISO9001 SGS HACCP
Place of Origin : China
MOQ : Negotiable
Price : Negotiable
Payment Terms : T/T, L/C, Western Union, MoneyGram
Supply Ability : 100 ton per Month
Delivery Time : 1-3days after payment
Packaging Details : 1~10 kg / Al-Pt bag,10kg / 25kg fiber drum
CAS : 98319-26-7
MF : C23H36N2O2
Shipping : DHL TNT FedEx HKEMS UPS
Use : Prostate enlargement, Pattern hair loss
Appearance : White powder
Type : the treatment of benign prostatic hyperplasia ( enlarged prostate ) and male pattern hair loss
Contact Now

Finasteride Medicine Raw Material Finasteride For Transgender women Excessive hair growth


Finasteride, also known as 17β-( N - tert - butylcarbamoyl )- 4- aza - 5α - androst - 1 - en - 3 - one, is a synthetic androstane steroid and 4 - azasteroid. It is an analogue of androgen steroid hormones like testosterone and DHT.

Finasteride is a lipophilic compound.

Society and culture

The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.

Harold Bornstein, Donald Trump's personal physician, stated Trump was taking finasteride to promote hair growth.


From 2005 to 2009, the World Anti - Doping Agency banned finasteride because it was discovered that the drug could be used to mask steroid abuse. It was removed from the list effective January 1, 2009, after improvements in testing methods made the ban unnecessary. Athletes who used finasteride and were banned from international competition include skeleton racer Zach Lund, bobsledder Sebastien Gattuso, footballer Romário and ice hockey goaltender José Théodore.

Brand names

Drug trade names include Propecia, marketed for male pattern baldness ( MPB ), and Proscar, for benign prostatic hyperplasia ( BPH ); both are products of Merck & Co. There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired on June 19, 2006. Merck was awarded a separate patent for the use of finasteride to treat MPB. This patent expired in November 2013.


Men in the US and Canada concerned about persistent sexual side effects "coined the phrase 'post finasteride syndrome', which they say is characterized by sexual, neurological, hormonal and psychological side effects that can persist in men who have taken finasteride for hair loss or an enlarged prostate". In 2012, a health advocacy group called the Post - Finasteride Syndrome Foundation was formed with the primary goal of finding a cure for the reported syndrome and a secondary goal of raising awareness. According to the company's 1Q2016 financial filing, Merck is a defendant in 1,385 product liability lawsuits which have been filed by customers alleging they have experienced persistent sexual side effects following cessation of treatment with finasteride.


Sexual dysfunction

Whether finasteride causes long - term sexual dysfunction in some men after stopping drug treatment is unclear. There are case reports of persistent diminished libido or erectile dysfunction after stopping the drug and the FDA has updated the label to inform people of these reports. A 2010 review found moderate quality evidence that finasteride increased the risk of sexual dysfunction, but not that people stopped using it because of sexual side effects.

When finasteride was originally approved for hair loss in 1997, the FDA approval review reported that it appears well tolerated, with the most common side effects being related to sexual function. In many people these side effects resolve if the medication is stopped and occasionally resolve even if the medication is continued. They additionally state " the sexual functioning questionnaire seems to have given a sensitive reflection of the disturbance on sexual functioning ".

A meta - analysis and systematic review found that sexual dysfunction, including erectile dysfunction, loss of libido, and reduced ejaculate, may occur in 3.4 to 15.8% of men treated with finasteride or dutasteride. This is linked to lower quality of life and can cause stress in relationships. There is also an association with lowered sexual desire. It has been reported that in a subset of men, these adverse sexual side effects may persist even after discontinuation of finasteride or dutasteride.


Test ItemsSpecificationTest Results
DescriptionWhite or off-white crystalline powderOff-white crystalline powder
Specific rotation-56°~-60°-58.2°
IdentificationIRMatches with working standardComplies
SolubilityFreely soluble in chloroform and in alcohol;
Very slightly soluble in water
Heavy metals≤10ppm<10ppm
Residue on ignition≤0.1%0.05%
Relative materialMaximum impurities≤0.5%0.36%
Total impurities≤1.0%0.52%
ConclusionThe specification conform with Enterprise standard

Product Tags:

steroid hormones


pharmaceutical intermediates

China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceuti Images

Inquiry Cart 0
Send your message to this supplier
To: Shanghai Poochun Industry Co.,Ltd
Characters Remaining: (0/3000)
Inquiry Cart 0